|Day's Range||120.17 - 120.90|
|52 Week Range||95.45 - 121.21|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.20%|
In 1Q17, Celgene (CELG) reported revenues of ~$3.0 billion, an increase of ~18% year-over-year (or YoY).
Of the 21 analysts covering AbbVie in June 2017, three have recommended “strong buys,” while six have recommended “buys.”
As record amounts of money have come into U.S.-listed exchange-traded funds this year, products of all stripes have seen interest from investors. But even in a year in which $200 billion has rushed into the space in only five months, it's not hard to find at least a few ETFs that have fallen out of favor with investors.